How A Coronavirus Blood Test Could Solve Some Medical Mysteries

By NPR News February 29, 2020

Listen

BY RICHARD HARRIS

As the coronavirus spreads more widely around the globe, scientists are starting to use a powerful new tool: a blood test that identifies people who have previously been exposed to the virus. This kind of test is still under development in the United States, but it has been rolled out for use in Singapore and China.

The current lab test used in the United States identifies people who are currently spreading the virus that causes COVID-19. That’s crucial information, but that test doesn’t reveal who had previously been infected. That’s important too for understanding the unfolding epidemic.

The other test, used widely in science and medicine, detects antibodies that people produce after they’ve become infected with a bacterium or virus. Those antibodies can appear in the blood one to three weeks after infection, and they’re part of the immune system’s response to infection.

The antibody-based tests can identify people who were not known to be infected “either because they never developed symptoms, or they had symptoms that were never correctly diagnosed,” says Lauren Ancel Meyers, a biology professor at the University of Texas at Austin.

That means the test can identify silent infections, as well as identifying people who were once sick but have recovered. If it turns out that many people got infected with the novel coronavirus but didn’t get sick, that means the virus is less likely to be fatal than it now appears. That’s just one insight the test could bring.

“One of the key questions we’re grappling with is what’s happening with children in this outbreak,” Meyers says.

Very few kids globally have ended up in the hospital. Is that because they’re not getting infected, or they’re getting infected but not getting sick? An answer to that question will help public health officials figure out whether it makes sense to close schools if there’s a big outbreak.

“Without knowing whether children are getting infected, or the rate at which they’re getting infected, or how severe the disease is in children, it’s really hard for us to project what the impacts of school closures might be,” she says.

The Centers for Disease Control and Prevention is currently developing an antibody test. But it’s now playing catch-up with scientists in both Singapore and China, who have produced their own tests and are putting them to use.

“I think that the Chinese laboratories have been amazingly fast,” says Dr. Stanley Perlman, a coronavirus scientist at the University of Iowa.

“I haven’t seen any publications to show they’re validated — and that’s of course what you want to know. But I think they are really capable of doing this pretty quickly.”

Validating the test is critical — otherwise you have no idea how many false findings you’re getting. You don’t want to flag people who have simply been infected with one of harmless coronaviruses that are already in wide circulation. And you don’t want a test that misses a lot of cases either.

Assuming the Chinese test is reliable, scientists there can figure out if these antibodies provide good protection against disease, and how long they persist. People who have been exposed to the virus might only be immune for a matter of months, Perlman says.

“You can imagine if the virus is around in a year and the antibodies wane that maybe someone could be reinfected,” Perlman says. “Again, this is speculative. We don’t know.”

If that turns out to be the case, the world could confront repeated waves of the disease rather than having it concentrated in one particularly bad year.

Because it likely takes the body one to three weeks to produce these antibodies, this test isn’t useful for tracking the illness in real time. That means it won’t replace the diagnostic test the CDC is currently running, and that is, after a delay due to technical problems, only now being expanded to health labs across the United States.

To understand where the epidemic is going, we need to know where it’s been.

For example, “has this virus ever entered the population undetected and been spreading?” asks Andrew Pekosz, a biologist at the Johns Hopkins Bloomberg School of Public Health. If in previous instances it induced only mild disease, “it may not have registered a large enough number of cases to get on the public health radar screen.”

Ebola and HIV both turned out to have existed for many years before scientists recognized the diseases those viruses cause. Scientists discovered that by running antibody tests on blood that had been stored long ago.

Pekosz says that because an antibody test for the new coronavirus can answer so many questions, demand for it will be fierce, “so you also have to think of scale of production and making sure that the test that you’re doing can be scaled up for widespread use.”

Since the federal government has declared a health emergency, the Food and Drug Administration can conduct a speedy review of a new test. But first the agency needs a product it can evaluate.

You can contact NPR Science correspondent Richard Harris at [email protected].

Doctors still doing damage control after pandemic fallout

When the COVID-19 pandemic reached the Inland Northwest almost three years ago, Dr. Max Williams started seeing a change in some of his patients that shocked him: People he had treated successfully for years no longer trusted him. Continue Reading Doctors still doing damage control after pandemic fallout

Rachel Sun January 10, 2023

A target chamber at LLNL National Ignition facility is made up of gleaming white and gray and yellow surfaces reflecting bars of yellow and white throughout the scientific experiment space.

Fusion reactions: Not just for your time-traveling DeLorean

The target chamber of LLNL’s National Ignition Facility, where 192 laser beams delivered more than 2 million joules of ultraviolet energy to a tiny fuel pellet to create fusion ignition… Continue Reading Fusion reactions: Not just for your time-traveling DeLorean

Dori Luzzo Gilmour December 20, 2022

Some hospitals in contingency operations, pediatric units rationing drugs

Idaho’s hospitals are feeling the strain from the “tripledemic” of RSV, flu and COVID-19, officials say. Dr. Jim Souza is the chief physician executive at St. Luke’s Health System in Boise. Continue Reading Some hospitals in contingency operations, pediatric units rationing drugs

Rachel Sun December 16, 2022